Östör, A., Van den Bosch, F., Papp, K., Asnal, C., Blanco Alonso, R., Aelion, J., . . . Kivitz, A. (2024). Efficacy and safety of risankizumab for active psoriatic arthritis: 100-Week results from the KEEPsAKE 2 randomized clinical trial.
Chicago Style CitationÖstör, Andrew, et al. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results From the KEEPsAKE 2 Randomized Clinical Trial. 2024.
MLA CitationÖstör, Andrew, et al. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results From the KEEPsAKE 2 Randomized Clinical Trial. 2024.
Warning: These citations may not always be 100% accurate.